IP Library Granted Patent US 7,923,204
Granted Patent B2
US 7,923,204 · App. 10/554,433 · Granted Apr 12, 2011

Forward mutation assay based on 5-fluorouracil resistance

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,923,204
App. No.
10/554,433
Granted
Apr 12, 2011
Kind
B2
Abstract

Disclosed herein is a novel forward mutation assay based on 5-fluorouracil (5-FU) resistance which utilizes a strain of Salmonella typhimurium derived from the Ames strain TA100. More specifically, the invention provides a high throughput alternative to the standard Ames mutation assay for the evaluation of the genotoxicity activity of compounds during an early stage of the drug development process. The invention also identifies the upp locus as a mutational target that is capable of detecting a diverse spectrum of mutagenic events and further describes a S. typhimurium tester strain, designated FU100 (his+, rfa, ΔuvrB, pkM101, 5-fluorouridine resistant) for use in the assay of the invention.

Claims (36)

1. A method for evaluating the genotoxic activity of a test compound comprising the steps of:

a) providing microbial indicator cells that are 5-fluorouridine resistant (5-FUR R ) at a desired cell density;

b) preparing a test compound for evaluation which may optionally include exposing the test compound to a metabolic activation system;

c) preparing a test sample comprising the test compound of b) and the microbial indicator cells;

d) incubating the test sample under conditions that promote the growth of the indicator strain;

e) evaluating the toxicity of the test compound;

f) incubating the test sample overnight under conditions that promote the growth of the indicator strain and expression of FU R phenotypes;

g) exposing the test sample to a selective concentration of 5-Fluorouracil (5-FU); and

h) determining the presence and number of 5-FU-resistant mutant indicator cells present in the test sample

wherein the presence of 5-FU-resistant indicator cells indicates that the test compound has genotoxic activity.

2. The method of claim 1 wherein the microbial indicator cells are Salmonella typhimurium cells.

3. The method of claim 2 wherein the microbial indicator cells are derived from Ames TA100 indicator cells such that the cells are histidine independent (his + ) and 5-fluorouridine-resistant (5-FUR R ).

4. A method for evaluating the genotoxic activity of a test compound comprising the steps of:

a) providing recombinant bacterial indicator cells that are 5-fluorouridine resistant at a desired cell density;

b) preparing a test compound for evaluation which may optionally include exposing the test compound to a metabolic activation system;

c) preparing a test sample comprising the test compound of b) and the microbial indicator cells;

d) incubating the test sample under conditions that promote the growth of the indicator strain;

e) evaluating the toxicity of the test compound;

f) incubating the test sample overnight under conditions that promote the growth of the indicator strain and expression of FU R phenotypes;

g) exposing the test sample to a selective concentration of 5-Fluorouracil (5-FU); and

h) determining the presence and number of 5-FU-resistant mutant indicator cells present in the test sample

wherein the presence of 5-FU-resistant indicator cells indicates that the test compound has genotoxic activity.

5. The method of claim 4 wherein the bacterial indicator cells are resistant to 0.2 ug/ml 5-fluorouridine.

6. The method of claim 4 wherein the bacterial indicator cells are further characterized by comprising a defective DNA repair system.

7. The method of claim 4 wherein the bacterial indicator cell comprises an error-prone DNA polymerase present on the pKM101 plasmid.

8. The method of claim 4 wherein the bacterial indicator cell comprises a mutation which facilitates transport of large compounds in the indicator cells.

9. The method of claim 1 wherein the metabolic activation system comprises a mammalian liver homogenate or extract.

10. The method of claim 9 wherein the metabolic activation system comprises a mammalian S9 preparation.

11. The method of claim 1 wherein the selective concentration of 5-FU is at least 1 ug/ml but not greater than 10 ug/ml.

12. The method of claim 11 wherein the selective concentration of 5-FU is at 2 ug/ml.

13. The method of claim 1 wherein the microbial indicator cells are prepared from a frozen stock of cells that is pretreated by growing the cells in the presence of 5-fluorooroticacid and uracil prior to preparing the frozen stock.

14. The method of claim 1 wherein the test sample is incubated overnight at 30° C.

15. The method of claim 1 wherein the microbial indicator cells are resistant to 0.2 ug/ml 5-fluorouridine.

16. The method of claim 1 wherein the microbial indicator cells are further characterized by comprising a defective DNA repair system.

17. The method of claim 1 wherein the microbial indicator cell comprises an error-prone DNA polymerase present on the pKM101 plasmid.

18. The method of claim 1 wherein the microbial indicator cell comprises a mutation which facilitates transport of large compounds in the indicator cells.

Assignments (3)
CHANGE OF NAME Recorded Aug 29, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028866/0511 →
MERGER Recorded Aug 27, 2012
From: MERCK SHARP & DOHME CORP.
To: SCHERING CORPORATION
Reel/Frame 028850/0515 →
CHANGE OF NAME Recorded Jan 22, 2010
From: MERCK & CO., INC.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 023834/0029 →